NeurogesX replaces DiTonno with Martell
This article was originally published in Scrip
San Mateo, California-based NeurogesX, which is focused on developing and commercialising pain management therapies, has appointed Ronald Martell as president and CEO. Prior to joining NeurogesX, Mr Martell was CEO at Poniard Pharmaceuticals. He replaces Tony DiTonno, who has retired.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.